Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026

AIM vs GNPX: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

GNPX Captures Overall Composite Edge (42.2 HOLD vs 39.4 SELL), While AIM Leads 3–1 on Growth & Valuation Pillars

GNPX Overall Winner 6-Pillar Tally: AIM 3 – 1 GNPX (2 Tie) Matrix Metrics: AIM 4 – 4 GNPX

As of Nov 20, 2026, Genprex, Inc. (GNPX) captures the overall head-to-head institutional edge over AIM ImmunoTech Inc. (AIM) on higher Unified Composite conviction (42.2/100 HOLD vs. 39.4/100 SELL) after splitting the core matrix 4–4 (led by Profitability & Quality), while AIM wins 3–1 across the 6-pillar growth and valuation breakdown. AIM trades at $0.11 (2.0x Forward P/E, -11724.2% operating margin) versus GNPX at $1.45 (N/M Forward P/E, 0.0% operating margin).

  • Growth vs. Quality Trade-Off: GNPX earns the overall head-to-head edge with a stronger Unified Composite Score (42.2/100 HOLD vs. AIM 39.4/100 SELL) and -4.68β · 96% Vol risk profile, whereas AIM leads top-line expansion (+4.0% YoY revenue growth, 0.71x PEG, and 3 of 6 institutional pillars) for higher-beta growth mandates.
  • Technical & Structure Timing Caution: AIM is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 27.1); meanwhile GNPX is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 26.6). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About AIM vs GNPX
AIM NYSE American
AIM ImmunoTech Inc.
Biological Products, (No Disgnostic Substances)
$0.11
-4.5% 1D
Market Cap $4.8M
TTM Revenue $95,000
Forward P/E 2.0x
Beta / 30D Vol 0.56β · 76% Vol
Unified Composite Score
39.4 / 100 SELL
Tech 25.0 Fund 43.0 Flow 50.0 Mom 59.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -17.5%), weak momentum, RSI 27
RSI-14: 27.1 · SMA20: $0.15 · SMA50: $0.17
GNPX NASDAQ Head-to-Head Winner
Genprex, Inc. Common Stock
Pharmaceutical Preparations
$1.45
-13.17% 1D
Market Cap $2.2M
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol -4.68β · 96% Vol
Unified Composite Score
42.2 / 100 HOLD
Tech 25.0 Fund 47.0 Flow 50.0 Mom 59.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -22.2%), weak momentum, RSI 27
RSI-14: 26.6 · SMA20: $2.00 · SMA50: $2.48

6-Pillar Scorecard Institutional Category Breakdown (AIM 3 – 1 GNPX)

Columns: Metric · AIM · GNPX
1. Valuation Multiples AIM
Forward P/E 2.0x N/M
Trailing P/E 2.0x N/M
PEG Ratio 0.71x N/M
EV / Revenue 50.4x N/M
2. Growth & Scale AIM
Revenue Growth (YoY) +4.0% +0.0%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) $95,000 N/A
Market Cap $4.8M $2.2M
3. Profitability & Quality GNPX
Gross Margin -23.2% N/A
Operating Margin -11724.2% 0.0%
Net Profit Margin 0.0% 0.0%
Return on Equity (ROE) -2382.3% -233.7%
4. Balance Sheet & Cash Flow AIM
Cash Generation (TTM) -$11M EBITDA N/A
Cash Flow Margin N/A N/A
Net Cash / Leverage -2382.3% ROE $11.26 Book/Sh · -233.7% ROE
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning Tie
Options Structure Phase UNCLASSIFIED UNCLASSIFIED
Current IV / %ile N/A (N/A) N/A (N/A)
Put/Call OI Skew N/A N/A
OBV Trend / Tech Phase NEUTRAL · Markdown NEUTRAL · Markdown
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: AIM (4) vs GNPX (4)
Institutional Metric AIM GNPX Criterion Row Edge
Market Capitalization
Scale
$4.8M $2.2M Larger Scale Tie
Trailing P/E Ratio
Valuation
2.0x N/M Lower Multiple AIM
Forward P/E Ratio
Valuation
2.0x N/M Lower Multiple AIM
Revenue Growth (YoY)
Growth
+4.0% +0.0% Higher Growth AIM
Operating Margin (TTM)
Profitability
-11724.2% 0.0% Higher Margin GNPX
Net Profit Margin
Profitability
0.0% 0.0% Higher Margin Tie
Return on Equity (ROE)
Capital Efficiency
-2382.3% -233.7% Higher ROE GNPX
52-Week Range Position
Momentum
0% ($0–$2) 11% ($0–$10) Stronger Trend GNPX
Beta / 30D Volatility
Risk Regime
0.56β · 76% Vol -4.68β · 96% Vol Lower Realized Risk AIM
Unified Institutional Score
Composite Signal
39.4 / 100 (SELL) 42.2 / 100 (HOLD) Higher Composite GNPX
Trailing 12M Revenue (USD)
Operating Scale
$95,000 N/A FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
-23.2% N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
0.71x PEG · 50.4x EV/Rev N/M PEG · N/M EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$11M EBITDA (-2382.3% ROE) N/A ($11.26 Book/Sh · -233.7% ROE) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon GNPX +2.05 pp
AIM: -28.82% · GNPX: -26.77%
3M Horizon AIM +9.05 pp
AIM: -54.88% · GNPX: -63.93%
6M Horizon GNPX +128.28 pp
AIM: -51.69% · GNPX: +76.59%
1Y Horizon GNPX +34.79 pp
AIM: -91.38% · GNPX: -56.59%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on AIM vs GNPX. Trailing 12-month operating profitability (AIM -11724.2% vs GNPX 0.0%) and valuation multiples (AIM 2.0x vs GNPX N/M Forward P/E) are benchmarked directly in Pillar 4 below.

AIM ADR TTM Benchmark FX-Normalized USD
TTM Revenue$95,000
Gross Margin-23.2%
Op. Margin-11724.2%
ROE / Fwd P/E-2382.3% · 2.0x
GNPX ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. Margin0.0%
ROE / Fwd P/E-233.7% · N/M

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
AIM UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact AIM Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
GNPX UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact GNPX Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
AIM Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $4.8M market capitalization and -11724.2% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
GNPX Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $2.2M market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ AIM vs GNPX Key Questions & Quantitative Answers

As of Nov 20, 2026, Genprex, Inc. (GNPX) captures the overall head-to-head institutional edge over AIM ImmunoTech Inc. (AIM) on higher Unified Composite conviction (42.2/100 HOLD vs. 39.4/100 SELL) after splitting the core matrix 4–4 (led by Profitability & Quality), while AIM wins 3–1 across the 6-pillar growth and valuation breakdown. AIM trades at $0.11 (2.0x Forward P/E, -11724.2% operating margin) versus GNPX at $1.45 (N/M Forward P/E, 0.0% operating margin). Growth vs. Quality Trade-Off: GNPX earns the overall head-to-head edge with a stronger Unified Composite Score (42.2/100 HOLD vs. AIM 39.4/100 SELL) and -4.68β · 96% Vol risk profile, whereas AIM leads top-line expansion (+4.0% YoY revenue growth, 0.71x PEG, and 3 of 6 institutional pillars) for higher-beta growth mandates. Technical & Structure Timing Caution: AIM is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 27.1); meanwhile GNPX is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 26.6). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

AIM leads the Growth & Scale pillar: AIM posts +4.0% YoY revenue growth and +0.0% YoY earnings growth on $95,000 TTM revenue (-23.2% gross margin, -11724.2% operating margin), compared with GNPX at +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin). On trailing 12-month operating scale, AIM generates $95,000 in USD-normalized revenue versus N/A for GNPX. In operating R&D and SG&A reinvestment, AIM deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for GNPX.

AIM screens cheaper on headline valuation multiples. AIM trades at 2.0x Forward P/E, 2.0x Trailing P/E, 0.71x PEG, and 50.4x EV/Revenue (unreported EBITDA margin), whereas GNPX trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against AIM (-2382.3% ROE) versus GNPX (-233.7% ROE) capital efficiency.

In options market volatility and institutional positioning, AIM carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.56β · 76% Vol realized risk). By comparison, GNPX carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (-4.68β · 96% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.